Ascendiant Capital Raises RenovoRx Price Target to $15.00
Ascendiant Capital has maintained its 'Buy' rating on RenovoRx while increasing the price target for the company's shares from $14.50 to $15.00.
Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Ascendiant Capital has maintained its 'Buy' rating on RenovoRx while increasing the price target for the company's shares from $14.50 to $15.00.
RenovoRx announced its financial results for the third quarter ended September 30, 2026, reporting record revenue of $1.07 million and providing updates on its commercial and clinical progress.
RenovoRx, Inc. announced that its CEO and CFO will present at the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 11, 2026.
RenovoRx, Inc. has scheduled the release of its third quarter 2026 financial results and business highlights for after market close on November 5, 2026.
RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared